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Abstract
Detecting breast cancer in its earliest stages significantly increases the likelihood
of being completely cured of the disease. Early detection via cancer mammogram
screening is central to breast cancer diagnosis. There is significant controversy,
however, surrounding the 2016 mammogram screening recommendation issued by
the U.S. Preventive Services Task Force (USPSTF). Why? The revised
recommendation cuts the frequency of screening in half and advises women to
begin routine screenings 10 years later than what previous guidelines
recommended. The justification for this change was that the benefits of screening
mammography increase with age, while the harms—especially the risk of a false
positive outcome—remain constant. This research evaluates the efficacy of the
USPSTF’s decision to change screening recommendations to minimize the false
positive frequency. Using a logistic regression model of data from the 2015
National Health Interview Survey, this analysis identifies the rate and demographic
correlates of false positive results. From these findings, this research considers the
ethical frameworks most appropriate for making policy recommendations in this
arena. The results of this analysis show that younger women, who have a lowerrisk of developing breast cancer compared to the average woman in their age
group, have a statistically significant (p<0.001) increased risk of a false positive
outcome. This paper proposes policy recommendations focused on transitioning
from a selective screening framework to an individualized risk assessment
framework.

Keywords
Health economics, screening mammography, breast cancer, false positive,
philosophy of medicine, policy evaluation
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1. Introduction
In the United States, nearly 1 in 8 women will develop invasive breast cancer over the
course of their lifetime (“U.S. Breast” 2017). Breast cancer death rates for women in the US are
higher than those for any other cancer, besides lung cancer (“U.S. Breast” 2017). According to the
National Health Institute, breast cancer is the second-leading cause of cancer death among women
in the United States and in 2015, an estimated 232,000 women were diagnosed with the disease
with 40,000 deaths (“SEER Stat Factsheets” 2015). Mammograms are one type of screening tool
that can be used to detect breast cancer in women, including for those women who have no signs
or symptoms of the disease. Although the primary goal of screening mammography is to decrease
mortality from breast cancer, it is important to emphasize that mammogram screenings are
diagnostic not preventative. In other words, mammograms cannot prevent breast cancer incidence;
they can only identify breast cancer and potential signs of breast cancer.
There are important benefits of screening mammograms, but some have argued that these
benefits are modest and do not outweigh the potential harms (“Mammography” 2011). On one
hand, early detection of breast cancer with screening mammography allows for the opportunity to
begin treatment at an earlier stage, when the cancer may be more treatable. Screening
mammography has been shown to reduce the number of deaths from breast cancer among women
ages 40-74, however there is no appreciable benefit to regular screening of women under age 40
(Mandelblatt et al. 2009). In light of this finding, The National Breast Cancer Coalition (NBCC)
contends that the benefits of screening mammography in reducing mortality are modest and instead
emphasizes the harms associated with screening. It may be that the harms and public health costs
of screening mammography may outweigh the modest benefits of the intervention.
One significant harm associated with screening is the false positive result. False positive
results occur when radiologists identify an abnormality on a mammogram but no cancer is actually
present. In this case, additional testing is usually conducted including invasive procedures like
biopsies. Beyond the physical consequences, false positive results can lead to significant psychic
costs including anxiety, distress, and physical discomfort (American Cancer Society, 2017). False
positive results are more common in younger women, women with dense breasts, women who
have had previous biopsies, women with a family history of breast cancer, and women who are
taking estrogen (“Mammograms” 2016). Moreover, the chance of having a false positive result
increases with the number of mammograms a woman has had (“Mammograms” 2016). It is
essential that screening recommendations consider the tangible and intangible costs of screening
while also ensuring its effective capture of the high-risk pool of women who are likely to develop
breast cancer in their lifetime. The ultimate goal of a screening recommendation, then, should be
to minimize the rate of incorrect results like the false positive, while maximizing the rate of true
positives, that is, the detection of cancer from screening.
With the ultimate purpose of screening mammography in mind, this study focuses on
analyzing the efficacy of the 2016 revised U.S. Preventive Services Task Force screening
mammography recommendations by specifically examining who benefits the most from the
revised recommendation. Given that a motivation for the USPSTF revision was to minimize the
rate of false positive incidence, this paper assumes that the individuals who benefit the most from
the USPSTF revision are those that are at a greatest risk for a false positive outcome. In particular,
this study will involve conducting an empirical analysis of false positive incidence and
demographic characteristics of individuals who received a mammogram in 2015 and participated
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in the 2015 National Health Interview Survey, the year preceding release of the USPSTF revised
guidelines.
Study Objectives and Overview
The central purpose of this study is to identify socioeconomic and demographic
characteristics of female patients who are most at risk of a false positive outcome, and therefore
would benefit the greatest from the U.S. Preventative Service Task Force (USPSTF) decision to
modify screening recommendations from annual to biennial screenings in order to minimize the
occurrence of the false positive. By conducting an empirical analysis that will identify significant
demographic factors that may serve as predictors of a false positive outcome, this study will
examine whether the revised USPSTF screening mammography recommendation is efficacious.
Moreover, this empirical analysis will be complemented with an ethical discussion
surrounding responsibility of care and the appropriateness of approaching screening
mammography recommendations from a utilitarian framework. Specifically, the philosophical
evaluation will focus on the application of the prevention paradox to the U.S. governmentsponsored screening mammography recommendation along with the ethical implications of using
a cost-benefit framework to evaluate the effectiveness of health interventions. Given that empirical
and economic analyses rarely ever include a philosophical component, a secondary purpose of this
study is to understand how incorporating a philosophical discussion to an empirical analysis may
serve to strengthen the results and proposed outcome of the analyses of interest.
My research question arises out of the understanding that reduced screenings result in a
reduced incidence of false positive results; but the female demographic most at risk for a false
positive outcome is still being understood. The false positive result incurs many associated costs,
included psychological costs and costs associated with added procedures. Yet, this cost may vary
for individuals based on certain demographic characteristics. Therefore, in conducting this
empirical analysis, I will investigate whether screening less in order to decrease the costs and
frequency of false positives, benefits individuals with certain demographic characteristics over
others. In summary, I have the following objectives for this study:

1)

2)
3)

To evaluate the efficacy of the U.S. Preventive Services Task Force’s decision to
change their screening recommendation from annual to biennial in order to minimize
the false positive frequency.
Identify the rate and demographic correlates of a false positive outcome, and the
patient pathway preceding a false positive outcome.
Investigate how closely the USPSTF recommendation aligns with certain ethical
frameworks.
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2. Background and Policy History
Screening Mammography
According to the American Cancer Society, 2 a mammogram is a low-dose x-ray that allows
doctors, specifically radiologists, to look for changes in breast tissue. According to the American
Cancer Society (ACS), the procedure of a mammogram involves a machine designed to look only
at breast tissue. The machine has two plates that compress or flatten the breast to spread the breast
tissue apart, since doing so gives results in a clearer picture and allows for the use of less radiation.
Mammograms can often detect breast cancer early, when the abnormality is small and before a
lump can even be felt. Mammograms are important diagnostic tools because treatment at an earlier
stage of a cancer’s progression is more likely to be successful. There are two types of
mammograms: screening and diagnostic. While screening mammograms are used to examine a
woman’s breasts regardless of whether or not symptoms are present, diagnostic mammograms are
used when changes in breast tissue have been reported or observed. This study will focus solely
on the results of screening mammograms.
Screening mammograms most often show abnormal areas in the breast. As mentioned
previously, mammograms are diagnostic in nature and not preventive, therefore they cannot
protect individuals from developing breast cancer. Instead, mammograms can only identify
potential abnormalities. A common analogy used to describe the purpose of screening
mammograms are strep throat tests. Strep throat tests, like mammograms, are not administered in
order to prevent the occurrence of sickness—in this case strep throat—but rather to diagnosis its
presence as a cause of observed symptoms. Similarly, mammograms cannot protect an individual
from developing breast cancer. Instead, the value of a mammogram rests in its ability to detect
cancer, where the best case scenario involves early detection such that the breast cancer may be
more treatable. Clinical trials, observational studies and modeling studies have demonstrated that
as women age the likelihood of avoiding a breast cancer death with regular screening
mammography gradually increases (USPSTF). In contrast, the harms of screening mammography
appear to remain constant or to decrease with age. While both types of mammograms expose the
breasts to small amounts radiation, the American Cancer Society has determined that any potential
harms associated with the radiation exposure are outweighed by the benefits of early detection of
breast cancer. Although it is very common to associate breast imaging with screening
mammography, mammograms are only one type of screening tool. In fact, only in the last several
decades, screening mammography has evolved and popularized substantially with advances in
radiologic technologies that aid in the detection and diagnosis of diseases.
In analyzing mammograms, radiologists look for different types of breast changes, such as
small white spots indicating calcification, lumps or tumors indicating masses, and other suspicious
areas that could be signs of cancer. When possible, doctors will compare old mammograms to new
ones (ACS, 2017). Findings that are not present on older mammograms may be cancerous,
warranting further tests. Mammogram reports also contain an assessment of breast density, which
is based on how fibrous and glandular tissues are distributed in the breast as opposed to how much
of the breast is made up of fatty tissue (ACS, 2017). Dense breasts, though not abnormal, are linked
to higher risk of breast cancer and can also make it more difficult to detect cancer from a
2

American Cancer Society, Mammography Basics: https://www.cancer.org/cancer/breast-cancer/screening-testsand-early-detection/mammograms/mammogram-basics.html
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mammogram. In order to evaluate mammograms, doctors use a categorical number system of 0-6.
This system is called the Breast Imaging Reporting and Data System or BI-RADS. By designating
results into specific categories, doctors have a universal description of results. The BI-RADS
categorization allows for accurate and consistent communication among the medical community
and between the doctor and patient. A detailed breakdown of the BI-RADS categories can be found
in the Appendix (Table 1).
Despite the many risk factors for breast cancer, fewer than 1 in 10 women who are called
back for additional testing are diagnosed with cancer (ACS, 2017). Often the cause of the followup is to clarify any areas of concern via more x-rays or an ultrasound, sometimes breast images
were not clear and need to be retaken or dense breast tissue may have made analysis difficult.
Follow-up requests are more common after a woman’s second mammogram, when there is a
previous mammogram available for comparison. Follow-up is also more common in women who
have not undergone menopause (ACS, 2017). In the case that the follow-up shows no suspicious
signs of cancer, then the outcome is a false positive. Alternatively, if the follow-up reveals
additional issues that raise questions or concerns, then a biopsy is sometimes ordered. If the
subsequent biopsy shows no signs of cancer, then the result is also considered a false positive.
Since a biopsy is often the only way to isolate cancer from other tissue abnormalities, this invasive
procedure—which requires removing a small piece of breast tissue to be checked under
microscopy—is relatively common.
Screening Mammography Limitations
Although mammograms are considered by the medical community to be the most reliable
screening test available, mammograms have limits. As shown in Figure 1, there are four possible
outcomes of a mammogram.

Figure 1: Screening Mammogram Outcomes
While true positive and true negative results correctly identify the existence, or lack
thereof, of cancerous tissue, false positive and false negative results occur when a mammogram or
radiologist falsely identifies or fails to identify breast cancer. False negative outcomes result when
a patient is incorrectly reported to not have breast cancer when they do, while a false positive
outcome results from a patient being incorrectly assumed to have breast cancer or signs of breast
cancer when they actually do not. Given these outcomes, in addition to maximizing the detection
of breast cancer, screening mammography recommendations must try to minimize the costs and
harms (including psychological costs) of screenings that result from incorrect results like false
positives and false negatives.
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The USPSTF found adequate evidence that:
screening for breast cancer with mammography results in harms for women aged 40-74
years. The most important harm is the diagnosis and treatment of noninvasive and invasive
breast cancer that would otherwise not have become a threat to women's health, or even
apparent, during her lifetime (that is, overdiagnosis and overtreatment). False positive
results are common and lead to unnecessary and sometimes invasive follow-up testing,
with the potential for psychological harms (such as anxiety).
According to the American Cancer Society Limitations of Mammograms webpage,3 given that
mammography sometimes leads to follow-up examinations, including biopsies, when there is no
cancer (a false positive result), a false positive outcome most often follows a woman's initial
screening mammogram. Factors that may increase the likelihood of a false positive include the use
of postmenopausal hormone therapy and having more mammographically dense breast tissue
(ACS, 2017). On average, of the women who are encouraged to have further testing following a
mammogram, 95% are ultimately shown not to have cancer. According to another US study, about
one-half of women experience a false positive result and about 19% undergo biopsy but do not
have cancer (Elmore et al, 1998). Given that the overall rate of breast cancer incidence is low, this
high rate of false positive incidence following additional testing is unsurprising.
The U.S. Preventive Services Task Force
The U.S. Preventive Services Task Force (USPSTF) is an independent panel of clinicians
and scientists commissioned by the Agency for Healthcare Research and Quality, an agency
housed under the Department of Health and Human Services. According to the U.S. Preventive
Services Task Force’s Final Recommendations Statement on Breast Cancer Screening,4
The USPSTF makes recommendations about the effectiveness of specific preventive care
services for patients without obvious related signs or symptoms. It bases its
recommendations on the evidence of both the benefits and harms of the service, and an
assessment of the balance. The USPSTF does not consider the costs of providing a service
in this assessment. The USPSTF recognizes that clinical decisions involve more
considerations than evidence alone. Clinicians should understand the evidence but
individualize decision-making to the specific patient or situation. Similarly, the USPSTF
notes that policy and coverage decisions involve considerations in addition to the evidence
of clinical benefits and harms.
Despite the screening mammography guidelines regularly released by the U.S. Preventive services
Task Force, there is significant controversy surrounding what age and how often women should
get mammograms. In 2002, the U.S. Preventive Services Task Force (USPSTF) recommended
screening mammography every 1-2 years for women beginning at age 40 years. Seven years later,
3

American Cancer Society, Limitations of Mammograms: https://www.cancer.org/cancer/breast-cancer/screeningtests-and-early-detection/mammograms/limitations-of-mammograms.html
4
Final Recommendation Statement: Breast Cancer: Screening. U.S. Preventive Services Task Force. November
2016.https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breastcancer-screening1
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on November 16, 2009, the USPSTF released new recommendations for breast cancer screening
(Hendrick et al, 2011). The revised statement recommended a change to biennial mammography
beginning at age 50 and ending at age 74 years on the basis that both annual and biennial screening
reduce mortality, but with biennial, the negative impacts are reduced (“Screening for Breast
Cancer”). The newest guidelines state the following:
The USPSTF recommends against routine screening mammography in women aged 40 to
49 years. The decision to start regular, biennial screening mammography before the age of
50 years should be an individual one and take into account patient context including the
patient's values regarding specific benefits and harms. The USPSTF recommends biennial
screening mammography for women between the ages of 50 and 74 years (“Screening for
Breast Cancer”, emphasis added).
In making this new recommendation, the USPSTF was informed by a systematic review of
published randomized clinical trials (Nelson et al, 2009) and the Cancer Intervention and
Surveillance Modeling Network (CISNET) modeling studies, which showed that despite a
significantly larger number of mammograms required when screening is started at age 40 versus
age 50 years, the result was only small gains in detection (Mandelbatt et al, 2009). 5 Table 2
provides a visual representation of these findings.
Recommendations by the USPSTF carry considerable weight. According to the Kaiser
Family Foundation, The U.S. Healthcare Reform Act, in its original form, included a specific
recommendation that “only USPSTF recommendations with a grade of A or B would receive
Medicare of Medicaid funding. An ‘A’ or ‘B’ letter grade indicates that the panel finds there is
high certainty that the services have a substantial or moderate net benefit” (“Preventative Services
Covered” 2015). The 2009 USPSTF report gave the recommendation that women 50-74 years
should receive a biennial screening a B rating. If their recommendations were followed, only
women ages 50-74 years would have insurance coverage to have a mammogram once every 24
months. Medicare recipients would also not be covered for screening mammography after the age
of 74 years. Moreover, “many third-party insurers follow Medicare's lead in deciding which
radiologic studies they will reimburse. Some states, such as Colorado, have tied funding for
screening mammography to USPSTF recommendations” (Hendrick et al, 2011). Therefore, the
implications of the USPSTF recommendations are significant in that they could lead to Medicare
and insurers funding only biennial screening for women 50–74 years old while shutting out women
under age 50 from access to coverage for screening mammograms.
Historically, “the decision to recommend screening mammography has hinged on
randomized controlled trials (RCT) results showing a statistically significant survival benefit
overall or for specific age groups” (Hendrick et al, 2011). In its 2009 screening mammography
recommendation, the USPSTF examined RCT data on screening mammography, as analyzed and
summarized in a detailed report by the Oregon Evidence-Based Practice Center at the Oregon
Health and Science University (Nelson et al, 2009). Moreover, the meta-analysis prepared
specifically for the 2009 USPSTF guidelines shows “a statistically significant benefit for women
39–49 years old alone, 50–59 years old alone, and 60–69 years old alone” (Hendrick et al, 2011).
However, the USPSTF decided to “depart from this standard of medical decision making, instead
5

A more detailed summary of the evidence considered by the USPSTF for the revised screening mammography
recommendations can be found in the literature review.
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focusing on the ‘number needed to invite’ to screening mammography in justifying its decision
against screening women 40–49 years old with mammography” (Hendrick et al, 2011). Ultimately,
the USPSTF estimated that “it would require inviting 1,904 women ages 40–49 years to save one
life and concluded that this was too many women screened for one life saved” (Hendrick et al,
2011).
This thesis will further analyze the justification and evidence considered for the USPSTF
revised recommendations in the ethical discussion. In their most recent recommendation, the
USPSTF concludes that “while there are harms of mammography, the benefit of screening
mammography outweighs the harms by at least a moderate amount from age 50-74 years and is
greatest for women in their 60’s” (Table 2) (USPSTF 2016). The statement also adds that “for
women in their 40’s, the number who benefit from starting regular screening mammography is
smaller and the number experiencing harm is larger compared with older woman” (USPSTF 2016).
As a result:
Women in their 40s must weigh a very important but infrequent benefit (reduction in breast
cancer deaths) against a group of meaningful and more common harms (overdiagnosis and
overtreatment, unnecessary and sometimes invasive follow-up testing and psychological
harms associated with false positive test results, and false reassurance from false-negative
test results). Women who value the possible benefit of screening mammography more than
they value avoiding its harms can make an informed decision to begin screening (“Final
Recommendation Statement” 2016).
Although it is difficult to precisely measure the extent of the benefits and harms associated with
beginning screening at age 40 rather than age 50, minimal research and modeling has been done
to predict the relative tradeoffs. According to a study conducted by CISNET in which modeling
studies were used to predict the lifetime benefits and harms of screening with contemporary digital
mammography at different starting and stopping ages and screening intervals, results showed that
the incidence of prevented breast cancer deaths when beginning screening age 40 rather than age
50 is insignificant (<1), yet the false positive incidence and rate of unnecessary follow-up biopsies
is almost two-fold (USPSTF). Once again, Table 2 displays the results of the study by comparing
the median and range across the models for predicted lifetime benefits and harms of screening
biennially from ages 50 to 74 years with screening biennially from ages 40 to 74 years (USPSTF).

Table 2: Lifetime Benefits and Harms of Biennial Screening Mammography per 1000 Women
Screened: Model Results Compared with No Screening, values reported are medians (ranges).
Source: USPSTF 2017
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Current Environment
Because of the uncertainty surrounding the benefits and harms of screening
mammography, there has been significant resistance to reducing the frequency and decreasing the
age range for screening. One of these is the American Cancer Society, which in 2003
recommended annual screenings from age 40 and continued regardless of a woman’s age.
Moreover, despite the USPSTF recommendation, currently all Marketplace health plans, which
are mandated by the 2010 ACA, and many other plans, must cover breast cancer mammography
screenings every 1-2 years for women over age 40 without charging a copayment or coinsurance,
even if a woman has not met her yearly deductible (“Preventive Care Benefits for Women”). Given
the contentious nature of the ACA, healthcare plans face the danger of only covering screening
mammograms based on the USPSTF guidelines. Consequently, the revised guidelines may limit
access to mammography for 22 million women between ages 40 and 49 (“USPSTF Guidelines”
2016). For this reason, there exists a significant divergence between the screening
recommendations issued by the federal government, the screening recommendations that insurers
are willing to cover, and the screening recommendations that the general public is recommended
to follow.

3. Literature Review
Risk Factors of Breast Cancer
According to the Center for Disease and Control (CDC), the risk for breast cancer is due
to a combination of factors. The main factors that influence risk are sex—being a woman—and
getting older. Most cases of breast cancer are found in women who are 50 years old and older
(CDC, 2017). Although some women will develop breast cancer without risk factors of which they
are aware, research has defined notable risk factors that can be used to predict the likelihood of
breast cancer incidence. These include: age, genetic mutations, early menstrual period, late or no
pregnancy, starting menopause after age 55, a sedentary lifestyle, being overweight or obese,
having dense breasts, using combination hormone therapy (i.e. estrogen and progesterone hormone
replacements), taking oral contraceptives (e.g. birth control pills), personal history of breast cancer,
personal history of certain non-cancerous breast diseases, family history of breast cancer, previous
treatment using radiation therapy, women who took the drug diethylstilbestrol (DES), and alcohol
(CDC, 2017) Although these risk factors may be used to help predict the likelihood of developing
cancer, it is important to note that most women have one or more of these risk factors, but still
never develop cancer in their lifetime.
Moreover, the rate of women that develop breast cancer in their lifetime varies, depending
on their race and ethnicity. Figure 2 shows how many women out of 100,000 got breast cancer
each year during the years 1994-2014. Accordingly, white woman had the highest rate of getting
breast cancer, followed by Black, Hispanic, Asian/Pacific Islander, and American Indian/Alaskan
Native women (CDC, 2017). However, the rate of women dying from breast cancer also varies
depending on race and ethnicity. Although White women are more likely to develop breast cancer,
according to the CDC, black women have been shown to be more likely to die of breast cancer
than any other racial group (Figure 3 Appendix).
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Figure 2: Female Breast Cancer Incidence Rates in the United States by Race and Ethnicity (19992014). Source: CDC’s National Program of Cancer Registries and National Cancer Institute’s
Surveillance, Epidemiology, and End Results program.
According to the USPSTF, “race and ethnicity are factors that have prompted concern
because of a growing disparity in breast cancer mortality rates. Moreover, “although White women
have historically had higher incidence rates than African American women, incidence rates have
come close to converging as of 2012 (128 vs. 124 cases per 100,000 women per year,
respectively)” (DeSantis et al, 2015). Despite the similar incidence rates, more African American
women die each year from breast cancer than White women, specifically about 31 vs. 22 breast
cancer deaths per 100,000 women per year, respectively (Howlader et al, 2014). However, the
reason for the disparity in breast cancer mortality between White and African American women is
not evident. Some research studies argue that it may be attributed to a differences in biology—
“African American women are disproportionately affected by more aggressive and treatmentresistant forms of breast cancer (that is, cancer with adverse histologic features, such as poorly
differentiated tumors and triple-negative phenotypes)” (Bauer et al, 2007 and Carey et al, 2006).
Unfortunately, according to the USPSTF, “these types of cancer may be the least likely to be
positively affected by screening programs, because they can grow so rapidly that they develop and
spread entirely within the timespan between screening examinations” (USPSTF).
The disparity in mortality rates between Whites and African Americans may also be due
to socioeconomic differences and health system failures (USPSTF). Multiple studies have shown
an association between African American race and experiencing delays in receiving health care
services for cancer, not receiving appropriate treatment, or not receiving treatment at all (Brawley
2009 and Griggs et al, 2007 and Roetzheim et al, 1999). However, according to the USPSTF,
African American women are also substantially underrepresented in randomized controlled trials
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of mammography screening; therefore, there is no high-quality evidence to conclude that screening
African American women more often or earlier than already recommended for the overall
population of women would result in fewer breast cancer deaths or a greater net benefit (USPSTF).
Risk Factors of a False Positive Result
Research has shown that women ages 40 to 49 made up the largest percentage of false
positive mammogram results with a recommendation for more imaging (33.1%) (“False-Positive
Mammogram” 2015). Women with dense breasts were also more likely to have false positive
results (Henderson et al, 2015). However, it is important to note that just because a mammogram
is abnormal does not imply breast cancer. Instead, the majority of abnormal mammograms have
benign causes. Causes of false positive occurrence include inaccurate interpretations and faulty
readings. Given that each woman’s breast looks different on a mammogram, breast imaging may
prove less accurate for some women than others. Other situations that put a woman at greater risk
for a false positive mammogram include “dense breast tissue, calcification, and benign cysts or
other masses” (Hook, 2010). False positive results from screening mammograms have also helped
fuel the debate on the value of breast cancer screening. One particular study suggests that women
who receive false positive results may be more likely to delay or avoid future mammograms
(Dabbous et al, 2017). Therefore, false positive incidence may have an impact on cancer outcomes
if women who have experienced false positive results avoid future mammogram screenings and
then later develop breast cancer. Consequently, those comparing the costs and benefits of screening
mammograms must be aware of the indirect costs of false positive outcomes as well.
Dalton et al’s (2006) population-based Danish study showed an increased risk of being
diagnosed with breast cancer for women with less education, lower disposable income, residence
in rural areas, and having no access to organized mammography screening. Apart from the access
to screening, these effects of social inequality were significant only for postmenopausal breast
cancers. As expected, access to mammography screening is an important factor for breast cancer
stage at diagnosis. Tosteson et al (2014) found that anxiety was significantly higher for women
with false positive mammograms as was future screening intention. Women who were younger
and in poorer health were also more likely to have a false positive outcome. Although the risk
factors for breast cancer and the consequences of false positive outcomes are researched
extensively, the demographic risk factors associated with false positive outcomes are still being
understood. Therefore, this thesis focuses on identifying the demographic correlates of false
positive incidence from screening mammography.
Ultimately, having a better understanding of the characteristics of women who are at the
highest risk of a false positive outcome can inform best practice to reducing the risk of false
positive occurrence. Moreover, identifying risk factors associated with a false positive result will
reveal the female demographic that benefits the most from the revised and controversial USPSTF
guidelines, given that a primary consideration for the revisions was to reduce false positive
incidence associated with screening mammography.
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4. Data and Methods
Assembling the Data Set
In order to identify the rate and demographic correlates of false positive incidence, data on
individual screening mammography cases was required. The National Health Interview Survey
reported this data, therefore this analysis utilizes the 2015 National Health Interview Survey6 given
that it reports screening mammography cases directly preceding the implementation of the revised
USPSTF screening mammography guidelines. Specifically, the 2015 NHIS cancer adult dataset
was merged with the 2015 NHIS adult file dataset in order to merge demographic characteristics
of screened women with data on specific screening mammography outcomes. The National Health
Interview Survey (NHIS) is a cross-sectional household survey conducted by the Center for
Disease Control and Prevention. The NHIS dataset provides a wide range of information about the
health of the U.S. population. Importantly, the NHIS collects information on the health of the U.S.
population using a multistage area probability design that permits a representative sampling of
households (Jatoi et al, 2006). Since the aim of this study was to discern any association between
demographic characteristics and false positive mammograms in a random sampling of the U.S.
population, the 2015 NHIS provided adequate data in its cancer module.
Within the NHIS dataset, basic health and demographic information is collected on all
household members, adults aged 18 or order, and children aged 1-17 years in the family core, adult
core, and child core components of the NHIS, respectively—although this study only focuses on
women aged 18 or older. In 2015, 33,672 adults with cancer completed the NHIS Adult Cancer
survey. Out of these, 18,601 females completed the survey. Since this study focuses on the
screening mammography outcomes of women, the dataset used in the analysis only includes
females. Questions ranging from family history, physical activity, diet, demographics, height and
weight, medical conditions, health behaviors, and health care access were asked. In the specific
cancer module, questions related to screening mammography history and family history of breast
cancer were asked.
Research Design
This study is concerned with evaluating the particular demographic characteristics that are
significant to predicting a particular patient pathway that results in a false positive outcome. For
this reason, three nearly identical logit regression models were run using three different samples
in the screening mammography patient pathway. Accordingly, each stage addresses a different
question regarding the effect of demographic characteristics on screening mammography
outcomes:
(1) First Sample: What are the demographic correlates of the decision to receive a
mammogram (controlling for initial risk assessment)?

6

2015 National Health Interview Survey. Source:
https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm
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(2) Second Sample: Of those who get a mammogram what are the demographic correlates of
receiving a recommendation for additional tests following initial mammogram
(controlling for initial risk assessment)?
(3) Third Sample: Of the women who followed up with additional testing, what are the
demographic correlates of a false positive outcome (controlling for initial risk
assessment)?
Three logit regression models were run on three different samples based on these defined screening
mammography patient pathways. Out of 33,672 adults, 10,887 women responded “yes” when
asked if they had ever received a mammogram (1). Out of the women who had received a
mammogram, 989 were recommended for follow up testing out of which 82 failed to follow the
recommendation (2). Out of the women who had follow up testing, 888 reported their outcome in
the survey, out of which 103 were diagnosed with cancer after following up and 785 females had
a false positive outcome (no cancer diagnosis after follow up testing) (3). Data were analyzed for
all three samples in three separate regression models.
Economic Models
Data Descriptions
Table 4 summarizes the descriptions of the 13 independent variables used in the economic
models for this analysis. The independent explanatory variables include general demographic
characteristics as well as breast cancer risk factors as control variables. In preparing the dataset,
many of the variables were recoded to fit a binary framework. Specific information regarding how
variables were transformed can be found in the “Variable Description” section of Table 4.
Summary statistics for the following variables can be found in the Appendix (Tables 17-19).
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Table 4: Independent and dependent variables and corresponding variable descriptions used in all
three economic models. Source: 2015 National Health Interview Survey
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First Model (Sample 1)
In the original 2015 NHIS cancer survey, a woman was asked ‘‘Have you ever had a
mammogram?’’ Out of 15,602 females that responded to this question, 10,887 women replied that
they had (69.78%), while the remaining 4,715 females reported otherwise. The first logit
regression model uses this sample and a binary response to the original question (1=Yes 0=No) as
the left-handed dependent variable. This model focuses on understanding the demographic
correlates of a women’s likelihood of getting a mammogram. It is important to note that in addition
to following a logit model, this model also uses Stata’s margins command to estimate and interpret
marginal effects at the means.
Mamm_Hadc = β0 + β1 (Cancer_Riskc) + β2 (Age) + β3 (Racec) + β4 (Marital_Statusc) +
β5 (Educationc) + β6 (Regionc) + ε

Second Model (Sample 2)
In the original survey, after having answered “Yes” to the initial question “Have you ever
had a mammogram?” women were asked the follow-up question “After your MOST RECENT
mammogram, were you advised to have more tests?” If the patient had follow up testing then they
were designated a “1” in the binary code, independent of the type of testing they had, if they were
not recommended for follow up testing, they were designated as “0” in the binary code. Out of the
10,887 females who had a mammogram, 9,898 (91%) were not recommended for a follow-up
while 989 (9%) were recommended for additional testing after an initial mammogram. This logit
regression model uses Stata’s margins command to estimate and interpret marginal effects at the
means.
Followup_Reccc = β0 + β1 (Cancer_Riskc) + β2 (Age) + β3 (Racec) + β4 (Marital_Statusc)
+ β5 (Educationc) + β6 (Regionc) + ε

Third Model (Sample 3)
In the original survey, if individuals followed up with additional testing after being advised
to do so, they were asked “as a result of these additional tests after your mammograms(s), were
you diagnosed with cancer?” If the answer was “No” then they were designated with a “0” in the
binary code and this outcome represented a false positive outcome. If the answer was “Yes” then
they were designated a “1” in the binary code. Out of the 888 females that followed through with
additional testing, 103 were diagnosed with cancer while 785 were not. As a result, false positive
incidence in this dataset occurred in approximately 88% of females who had follow up testing and
in approximately 7.2% of females who had a mammogram. As in the previous stages, in addition
to following a logit model, this model also uses Stata’s margins command to estimate and interpret
marginal effects.
Cancer_Diagnosisc = β0 + β1 (Cancer_Riskc) + β2 (Age) + β3 (Racec) + β4
(Marital_Statusc) + β5 (Educationc) + β6 (Regionc) + ε
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5. Data Analysis and Visualization
Predicting the Likelihood of Receiving a Mammogram (Sample 1)
In examining the demographic predictors associated with a woman’s response to whether
or not she had a mammogram, several characteristics stood out including age, marital status, and
educational attainment level. Approximately 82% of females in the dataset who were assessed to
be more likely than the average woman in their age group to develop breast cancer (e.g. higher
individual risk assessment), had mammograms. Of the women that were less likely than the
average woman in their age group to develop breast cancer, around 76% had a mammogram not
holding any other factors constant (Table 5). This is to say, a woman’s likelihood of receiving a
mammogram increased with her personal risk of developing breast cancer compared to the average
woman in her age group, not controlling for several other factors (Table 5).

Table 5: Cross tabulation of a woman’s response to whether or not she had a mammogram and her
personal risk of developing breast cancer compared to the average woman in her age group.
Importantly, around 12% of White females in the dataset had a higher risk of developing breast
cancer compared to the average woman in their age group. However, 43% of White females were
less likely than the average woman in their age group to develop breast cancer. By contrast, only
8% of Hispanic females were high-risk, and only 8% of Black females were high-risk.
Given the output of the binary logit regression model (Model 1) for Sample 1, there are
several important points to note (Table 9). There was a significant negative effect of risk-level on
likelihood of having a mammogram. That is to say, compared to individuals that were at a higher
risk than average of developing breast cancer, women who were at a lower risk than average of
developing breast cancer were 7.5% less likely to have had a mammogram holding all other factors
constant (p<0.000). Women who were equally at risk of developing breast cancer as the average
woman in their age group were also almost 7% less likely to have had a mammogram than high
risk women, holding all other factors constant (p<0.000). Most significantly, women with an
unknown risk of developing breast cancer were 62% less likely to have had a mammogram than
their high-risk counterparts, holding all else constant (p<0.000). Therefore, it can be inferred that
a females’ individual risk of developing breast cancer has a significant effect on likelihood of
receiving a mammogram. Reasons for this effect will be discussed later. Evidently, it seems that a
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woman’s likelihood of having a mammogram significantly increases if she is at a higher risk or
aware of her personal risk of developing breast cancer in her lifetime (Table 9).
Age was another significant predictor of a woman’s response to whether or not she had a
mammogram. A woman’s likelihood of having a mammogram increases by almost 2% every year,
holding all other factors constant (p<0.000). This means that a woman’s likelihood of receiving a
mammogram increases by 20% every 10 years. Given the social norm surrounding routine
mammogram screenings for women, it comes as no surprise that as a woman ages, she is more
likely to have had a mammogram than her younger counterparts, regardless of her personal risk of
developing breast cancer (Table 9). Marital status was yet another significant predictor of a
female’s likelihood of having had a mammogram. Widowed women were 20% less likely to have
had a mammogram than their married counterparts (p<0.000) while single women were also about
4% less likely to have had a mammogram compared to their married counterparts (p<0.000). Race
was not a significant predictor of a woman’s likelihood of having had a mammogram, however
according to the results of the model (Table 9), it appears that Black women were 2% more likely
than White females to have received a mammogram, holding risk of developing breast cancer
along with other characteristics constant (p<0.036). Moreover, Asian women were 3% less likely
than White women to have had a mammogram (p<0.006). Hispanic women were not significantly
more or less likely than White women to have received a mammogram.
Although the effect of the region a woman resides on her likelihood of receiving a
mammogram was statistically significant holding all else constant (Table 9) the effect size was
small (Table 8). According to Table 8, 68-72% of women in every region in the United States
received a mammogram. Moreover, the difference in the likelihood of having received a
mammogram based on region is small (<5%). Nonetheless there may be important reasons for why
region of residence may have a significant effect on the likelihood that a woman has received a
mammogram—holding all other factors constant—including variations in access to or quality of
healthcare.

Table 8: Cross tabulation of a woman’s response to whether or not she had a mammogram and the
region of the United States where she reportedly resides.
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Table 9: Logit regression model with robust standard errors and marginal effects where the
dependent variable is a female’s binary response to whether or not she had a mammogram.
Independent explanatory variables include personal risk of developing cancer, age, race, marital
status, educational attainment, and region of residence.
Predicting the Likelihood of a Recommendation for Additional Testing (Sample 2)
If women responded, “Yes” to having had a mammogram, they were then asked the followup question of whether or not they were recommended for additional testing after the initial
mammogram. A second model was examined in order to identify socioeconomic and demographic
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characteristics that could predict a woman’s likelihood of being recommended for follow up testing
(Table 12). A preliminary analysis of the data showed that around 20% of high risk women were
recommended for additional testing, while only 6% of low-risk women and almost 9% of averagerisk women were recommended for follow up testing (Table 10). Moreover, close to 10% of White
females, 9% of Hispanic females, 7% of Black females, and 10% of Asian females in the dataset
were recommended for additional testing (Table 11).

Table 10: Cross tabulation of personal risk of breast cancer compared to the average women in the
female patient’s age group and a woman’s response to whether or not she was recommended for
additional/follow-up testing.

Table 11: Cross tabulation of race and a woman’s response to whether or not she was
recommended for additional/follow-up testing.
According to the results of the model predicting likelihood of being recommended for
additional testing (Table 12), a female’s personal risk of developing breast cancer was once again
a significant variable (p<0.001). Specifically, a woman who is less likely than the average woman
in her age group to develop breast cancer is about 12% less likely than women at a higher risk than
average to be recommended for a follow up, holding all else constant (p<0.000). A woman who is
at average risk is 10% less likely than her high-risk counterpart to be recommended for additional
testing, holding all else constant (p<0.000). For this reason, it is evident that holding all other
characteristics constant, a woman’s likelihood of being recommended for follow-up testing
increases with her personal risk of developing breast cancer.
Age was another significant predictor of likelihood of follow-up in Sample 2. Specifically,
the older a woman is, the less likely she is recommended for a follow-up, although the effect size
is small (β <0.001). With regards to race, comparison between Black females and White females
regarding the likelihood of follow-up was the only significant effect. In particular, Black females
are about 2% less likely to be recommended for a follow-up than White females (p<0.024). Marital
status was an insignificant predictor of the likelihood of being recommended for follow-up as was
region of residence (Table 12). Educational attainment level, however, was a significant predictor
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of the likelihood of being recommended for additional testing. As it appears, the higher the
educational attainment of a female, the more likely she is compared to her lesser educated
counterparts to be recommended for additional testing, holding all else constant (p<0.002).

Table 12: Logit regression model with robust standard errors and marginal effects where the
dependent variable is a binary response to whether or not a female was recommended for
additional/follow up testing after an initial mammogram.
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Predicting the Likelihood of a False Positive (Sample 3)
If a woman responded, “Yes” to being recommended for additional testing after an initial
mammogram, and if she followed through with the additional testing, she was asked the followup question of whether or not the additional testing resulted in a cancer diagnosis. Out of the
women who had follow up testing, 888 reported their outcome in the survey out of which 103 were
diagnosed with cancer after follow-up and 785 females had a false positive outcome (no cancer
diagnosis after follow-up testing). 82 women reported that they did not follow-up with additional
testing despite being recommended for it (Table 13). Out of these women, almost 25% reported
they did not follow-up because it was too expensive and/or their insurance did not cover the cost,
about 20% reported they put it off or did not get around to it, and 5% reported it was too unpleasant,
painful, or embarrassing. 34% cited some other reason (Table 13).

Table 13: Reported reasons for why women did not follow-up with recommendation to pursue
additional testing after initial mammogram.
Of the women who did follow through with the recommended additional testing, those that
were most likely to have a false positive outcome had a lower than average personal risk of
developing breast cancer, as expected (Table 14). That is, 73% of high-risk females, 94% of lowrisk females, and 94% of average-risk females had a false positive outcome (Table 14). Given that,
in general, the rate of cancer incidence is low, it was expected that the majority of women who got
a follow up would have a false positive outcome (88%).

Table 14: Cross tabulation of personal risk of breast cancer and a woman’s response to whether or
not she was diagnosed with cancer after additional testing, where a negative diagnosis was
considered a false positive outcome.
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Of the women who had a false positive outcome, about 70% were White, 13% were
Hispanic, 12% were Black, and 5% were Asian (Table 15). According to Model 3, holding all
other factors constant, a female’s personal risk of developing breast cancer was significant to
whether or not she had a false positive outcome. As shown in Table 16, women who were at a
lower risk of developing breast cancer compared to the average woman in their age group were
significantly less likely to have a positive cancer diagnosis and therefore more likely to have a
false positive outcome compared to their high-risk counterparts (p<0.000). Age was another
significant predictor of a false positive outcome, holding all other factors constant. Since a woman
was more likely to have a positive cancer diagnosis as she ages, it can be said that a woman’s
likelihood of having a false positive outcome decreases as she ages (Table 16).
Race was only significant as it concerned the comparison between Black females and
White females. In particular, Black females were 6% less likely to have a cancer diagnosis than
White females, and therefore more likely than White females to have a false positive outcome
(p<0.001). Marital status, educational attainment level, nor region of residence were found to be
significant predictors of a female’s likelihood of having a false positive outcome, holding all other
factors constant (Table 16).

Table 15: Cross tabulation of race and a woman’s response to whether or not she was diagnosed
with cancer following additional/follow-up testing. A false positive outcome results from a
negative cancer diagnosis (No=0) after follow-up testing.
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Table 16: Logit regression model with robust standard errors and marginal effects where the
dependent variable is a binary response to whether or not a female was diagnosed with cancer
following additional/follow up testing after an initial mammogram.
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6. Discussion
Discussion of Empirical Results
Overall, results show demographic characteristics that can serve as significant predictors
of a false positive result. Moreover, there are demographic characteristics that are significant
predictors of health outcomes in the patient pathways preceding a false positive outcome including
the likelihood of having had a mammogram and being recommended for additional testing
following an initial mammogram. Personal risk of developing breast cancer was one predictor that
remained significant across all three samples of the patient pathway. Women at a higher risk than
average of developing breast cancer were more likely to have had a mammogram, more likely to
be recommended for follow-up testing, and more likely to be diagnosed with cancer, as expected.
If a woman has a high risk of developing breast cancer—due to family history or other risk
factors—she is likely to be extra cautious regarding her breast health, this includes scheduling
regular screenings. The reverse of this outcome also holds true as well: women who are less likely
to be at risk of developing breast cancer compared to the average woman in their age group were
less likely to have had a mammogram, less likely to have been recommended for follow-up testing,
and more likely to have had false positive outcome, holding all other factors constant. Younger
women, in general, have lower breast cancer incidence rates. If these low-risk women are
nonetheless getting routine screenings, it is expected that they will be at a higher risk of incurring
a false positive outcome. This significant relationship between personal risk of breast cancer and
health behavior was expected, and served as a justification for the 2016 revision to the USPSTF
guidelines.
Region of residence had a significant effect on a woman’s likelihood of having had a
mammogram. In particular, women from the Northwest were significantly more likely than women
from the Midwest, South, and West to have received a mammogram. There are several potential
reasons for this difference in effect, however the most likely cause is due to regional differences
in access to healthcare and preventative health services. Another significant predictor of a female
patient’s health outcomes was marital status. Single women, whether widowed or never married,
were less likely to have a mammogram than their married or partnered counterparts. Several
reasons could account for this outcome. For one, spousal/partner support can serve as a source of
encouragement to follow recommendations for routine mammograms. Health insurance may also
play a role in this health outcome. Married women may have the support of their partner’s health
insurance to cover mammogram screenings, while widowed or single women may not. Marital
status only served as a significant predictor of the likelihood that a woman had a mammogram, not
the likelihood that she would be recommended for follow-up testing or whether she would have a
false positive outcome. Since the risk of a false positive outcome increases with a woman’s
frequency of screenings and because women that are single or widowed are less likely to have
mammograms, these women—by default—are less likely to incur a false positive outcome. This
assertion is not definitive, but rather just one possible explanation for why single or widowed
women have a less apparent risk for a false positive outcome (Table 15), though this overall effect
was insignificant (p>0.846).
Race was not entirely predictive excluding the outcome of Black females compared to
White females. Black females were 2% more likely than white females to have had a mammogram
(p<0.036), but about 2% less likely to be recommended for additional testing (p<0.024), and 6%
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more likely to have a false positive outcome if they were recommended for additional testing,
holding all other factors constant (p<0.001). One explanation for this outcome is that White women
have, on average, the highest rate of getting breast cancer followed by Black women (CDC,
2017)—therefore, Black women are more likely to have a higher likelihood of incurring a false
positive when compared to White women since their overall rate of breast cancer incidence is
lower.
Educational attainment level was a significant predictor of a woman’s health behavior.
Women that were more highly educated were more likely to have had a mammogram and more
likely to be recommended for follow-up/additional testing, although educational attainment had
no significant effect on a woman’s likelihood of having a false positive outcome. One explanation
for this is that educated women are more likely to also be knowledgeable about their health and,
as a result, are more likely to practice healthy behaviors including routine breast screenings. These
women may be more knowledgeable about screening recommendations than their less educated
counterparts. On another note, educated women are also more likely to have higher incomes and
therefore they are more likely to be able to afford routine mammograms—whether through their
health insurance or out-of-pocket.
Age was by far the most significant variable across all stages of the patient pathway,
holding all other factors constant. Arguably, age is the most significant driver of a woman’s
reasons for getting a mammogram. As she ages, however, she is less likely to be called in for a
mammogram (though not as significantly so), and finally she is more likely than her younger
counterparts to be diagnosed with cancer after additional testing. Such an outcome was expected
because as woman age, their number of screening mammograms increases. The more
mammograms a woman has had, the easier it is for a doctor to interpret a mammogram report when
there are past mammograms to use as a comparison. For this reason, the need for a follow-up to
clarify results may decrease. Alternatively, then, younger women who have less experience with
screening mammograms are at a higher risk for a false positive outcome. Such an outcome is
expected as it served as the primary justification for why the USPSTF revised their
recommendations to starting routine screenings 10 years later than their previous recommendation
advised, in order to reduce the false positive incidence in young women.
Therefore, it appears as though the data prove consistent with the guidelines advised by the
USPSTF. Those benefiting most from the revision are females that are at a greatest risk of a false
positive outcome. According to the models run in this analysis, women most at risk of a false
positive outcome include young women that are at a lower risk of developing cancer than the
average women in their age group. In delaying routine mammograms to age 50, instead of 40, the
USPSTF intends to reduce the false positive incidence in young, low-risk women who are most at
risk for this outcome.
Philosophical Discussion
As determined from the empirical analysis, the revised USPSTF recommendations benefit
women who are younger and at a lower risk of developing breast cancer. It is for these women that
annual screenings starting 10 years later than advised by the ACS, minimizes their likelihood of
receiving a false positive outcome. The USPSTF reported that “the likelihood of avoiding a breast
cancer death with regular screening mammography increases with age [...] however, the harms of
screening mammography either remain constant or decrease with age. Therefore, the balance of
benefits and harms improves with age” (USPSTF). As a result, for women in their 40s, the
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percentage who benefit from starting regular screening mammography is smaller and the
percentage experiencing harm is larger compared to older women. This fact is consistent with the
results determined from the empirical analysis: younger women burden the costs of false positives
at a higher rate than older women do. Several philosophical questions arise out of this result
including those pertaining to the responsibility of care and the ethics of valuing societal risk over
an individual's personal risk acceptance when defining recommendations that affect individual
health outcomes.
Prevention Paradox
For one, the USPSTF follows a selective screening framework given that their
recommendations pertain to women that fit a certain demographic criterion. This type of selective
screening framework should not be considered to be the best approach for decreasing the incidence
of breast cancer related deaths. Though seemingly utilitarian in nature, this framework falls short
for several reasons. Consider the prevention paradox. In introducing the prevention paradox to this
discussion, it is important to once again emphasize that screening mammograms are not
preventative. However, although screening mammography does not prevent breast cancer
incidence, it can and often does prevent breast cancer related death. As defined by the World
Health Organization’s World Health Report7, the prevention paradox states that preventing small
risks in large populations may avoid more adverse health outcomes than preventing large risks in
a smaller number of high risk individuals. In the case of screening mammography guidelines, then,
it addresses the question of whether tailoring a recommendation that focuses on preventing breast
cancer related deaths in a smaller number of high risk individuals—as the USPSTF selective
screening guidelines does—has a greater benefit to health outcomes than tailoring
recommendations to prevent smaller risks in large populations—as a more universal screening
recommendation does.
The USPSTF functions under the notion that recommendations should be focused on
preventing larger risks in a smaller number of high risk individuals, which is why the guidelines
advise starting routine screenings at age 50 instead of age 40. However, there remains a number
of otherwise low risk individuals who will still develop breast cancer in their lifetime—whether
from environmental or other unpredictable factors. The prevention paradox supports populationbased interventions rather than those aimed at selective, high-risk individual targets to ensure that
those low-risk individuals who will—despite being at low-risk—develop breast cancer can still
get screened and maximize their chances of preventing breast cancer related death. For this reason,
a selective screening framework may not be as effective as a more inclusive screening framework.
Rose’s theorem further affirms this idea: a large number of people exposed to a small risk
may generate many more cases than a small number exposed to high risk (Rose, 1992). Therefore,
in order to minimize breast cancer related deaths at the population level, it does not make sense to
completely shut out low risk individuals—women ages 40-50—out of which a percentage of these
women will still go on to develop breast cancer in their lifetime even as low-risk individuals. As a
result of the prevention paradox and the current USPSTF screening mammography guidelines,
there exists a philosophical disconnect. The USPSTF framework may not be maximizing benefits
of screening mammography while minimizing its harms to the extent that was presupposed.

7

World Health Organization, Chapter 6 World Health Report:
http://www.who.int/whr/2002/chapter6/en/index1.html
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Beneficence and Patient Autonomy
Nonetheless, there exist significant detriments to approaching screening mammography
from a utilitarian framework—valuing the overall prevention of cancer-related deaths at the lowest
cost. The USPSTF screening mammography guidelines do not entirely account for individuals
who, despite being outside of the recommended criteria for a mammogram, would individually
benefit more from a mammogram for reasons such as minimizing anxiety from not getting
screened. These individuals may find it costlier to not get screened rather than incurring a false
positive outcome. Since the overall aggregate benefits and harms of screening mammography are
difficult to determine, patient autonomy should be a central factor in determining whether a woman
decides to get a mammogram or not.
Chief among the objections to the USPSTF recommendations was that the panel had
insufficiently valued patients’ lives or allowed cost considerations to influence recommendations
(Plutynski, 2012). In a sense, the USPSTF guidelines show an inconsideration for patient
autonomy and beneficence. As Norman (2012) notes, “since this time of intervention is performed
on healthy individuals, the ethical requirements in the cases of screening programs are very high,
because the risks of damage are not balanced, against real suffering (a clinically manifested
disease), but are anchored in a potential future of illness and death.” Given the exclusive nature of
the USPSTF guidelines: non-maleficence (do not harm) and beneficence (The desire to promote
patient’s wellbeing) become difficult to adhere to for health practitioners, especially when what is
deemed best for an individual patient may not align with what is recommended by screening
mammography guidelines. This result can have an increasingly dangerous outcome if screening
mammography guidelines dictate coverage requirements for screening mammography.
By narrowing the parameters of screening eligibility, selective screening may be a worse
framework for screening mammography than even a universal screening one given the violation
of patient autonomy and beneficence. In contrast, universal screening allows for an entire
population to be screened to ensure no cancer goes undiagnosed, albeit generating unnecessary
costs as it does. However, despite the benefits of universal screening over selective screening there
still exists one framework that may still prove more reliable: individual risk assessment.
Given the variance in breast cancer risk and personal risk acceptance, surveillance and
primary prevention adapted to each patient’s individual risk level may be the most effective
screening mammography recommendation framework. Moreover, this framework may be also
prove the most effective use of resources for preventing, detecting, and improving breast cancer
survival (Pharoah et al, 2008). This risk-level specific standard of care is continually garnering
evidence of its effectiveness to produce a population-level reduction in breast cancer mortality. An
individual risk assessment framework involves a shared decision between the doctor and her
patient regarding when and how often to get screened. Clinical providers discuss personalized risk
information with patients while patients discuss their personal risk acceptance, addressing
questions like whether or not they would be willing to incur a false positive outcome to alleviate
any concerns regarding their breast health. Such an approach to cancer surveillance and prevention
is consistent with trends towards patient-centered care (“Institute of Medicine/Committee on
Quality Health Care in America”) and individualized medicine (Hamburg et al, 2008). In this way,
individual risk assessment can be characterized as a tool for individuals who can then be
encouraged to take responsibility for their own health (Anderson et al, 2012).
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Quantifying the Value of Human Life
The USPSTF’s screening mammography guidelines bring to light another very
controversial philosophical discussion, this time centered on quantifying the value of human life.
This discussion is not confined to the USPSTF’s framework; however, it is a discussion that arises
out of justifying a cost-benefit framework as a basis for recommending preventative care. Costbenefit analyses translate all relevant considerations into monetary terms. Therefore, in the case of
the USPSTF guidelines, the costs of screening mammography: from additional testing, to
overdiagnosis, misdiagnosis, and psychological costs, were quantitatively compared to its benefits:
including the saving of human lives and prevention of breast cancer. These considerations are all
presented in terms of dollars. Proponents of cost-benefit analysis make two basic arguments in its
favor:
First, use of cost-benefit analysis ostensibly leads to more “efficient” allocation of society’s
resources by better identifying which potential regulatory actions are worth undertaking
and in what fashion. Advocates of cost-benefit analysis also contend that this method
produces more objective and more transparent government decision-making by making
more explicit the assumptions and methods underlying regulatory actions
(Heinzerling et al, 2002).
However, such a task is implausible in practice. For one, cost-benefit analyses cannot
produce outcomes that maximize benefits to society when the process of reducing life, health, and
the natural world to monetary values is inherently flawed (Heinzerling et al, 2002). Moreover,
cost-benefit analysis implicitly equates the risk of death with death itself, when these two things
should be accounted for separately in forming regulations for preventative services. Cost-benefit
analysis also ignores the fact that “citizens are concerned about risks to their families and others
as well as themselves, that market decisions are generally very different from health-related
decisions, and of the incomparability of many different types of risks to human life” (Heinzerling
et al, 2002). The kinds of problems which arise in attempting to define the value of human life in
monetary terms also arise in evaluating the benefits of protecting human health.
This is not to say that cost-benefit analyses cannot be a useful decision-making aid. It
certainly should be used as a tool for assessing decisions that affect populations. However, when
it comes to screening recommendations and an individual’s health, the value of human life should
be a consideration placed upon the individual and not on the government. That is, a personal costbenefit assessment should take precedence over a government-sponsored cost-benefit when
deciding about a personal plan for getting screened. The value individuals place on life, or rather
on the risk of death, is certainly dependent on factors that the government cannot be responsible
for deciding on. The effectiveness of cost-benefit assessment, then, is that of distributive justice
and to force considerations of the issue of placing values on health outcomes (Heinzerling et al,
2002)—therefore to promote the cause of efficiency in health care. In this way, ethics and
economics need not necessarily have polarizing perspectives when evaluating health interventions,
let alone screening mammography recommendations. A health intervention that has no
consideration of economics can be equally as dangerous as a health intervention without ethical
considerations: since “without a wider use of economics in healthcare, inefficiencies will abound
and decisions will be made less explicitly and hence less rationally than is desirable [...] the price
of inefficiency in explicitness and irrationality in health care is paid in death and sickness”
(Mooney, 1980).
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Methodological Biases in Evidence
There are several methodological issues raised in cancer screening. Some of these include:
the potential biases that may infect a trial of screening effectiveness, the problem of base rates in
communicating risk, and the trade-offs involved in a judgement of screening effectiveness
(Plutynski, 2012). Furthermore, a recently published systematic review in the British Medical
Journal on the adverse effects of cancer screening, found that only a third of randomized controlled
clinical trials was concerned in measuring and controlling for potential harms of screening
intervention (Norman, 2012):
This article is very important because it has a direct effect upon the practice of health
professionals, who cannot address security parameters on cancer screening interventions
with their patients, since there is an information selection bias that emphasizes only the
positive aspects of screening, for lack of controlling and monitoring of potential harms in
most screening clinical trials (Norman, 2012).
From an ethical stance, this uncertainty undermines the patients’ ability to practice autonomy, by
creating false empowerment, since women do not have a more complete view on the potential
harms and benefits of breast cancer screening programs (Norman, 2012). In order to secure patient
autonomy, there is a need for the research and justification behind guidelines to be more
transparent. Moreover, the language explaining relevant research findings and shortcomings
should be neutral and accessible, so that individuals can make informed decisions about their own
health.

7. Conclusions
Policy Recommendations
In recognition of the results of the philosophical and empirical analysis, several policy
recommendations should be implemented in order to alleviate any recurring controversy
surrounding the revisions to the USPSTF guidelines. It is important to recognize that changes in
recommendations have been met with controversy partly because the public is not aware of the
reasons for the revisions—that is to minimize a woman’s risk of having a false positive outcome.
Therefore, information, education and communication (IEC) campaigns educating women on the
causes for the revisions and on the research behind screening mammography recommendations
should be set in place. The research—including shortcomings—behind interventions should be
neutral and accessible so that a wide audience may interpret these findings in order to make better
informed decisions regarding their health.
In addition, interventions should be implemented focusing on an individualized risk
assessment framework of screening. That is, women should consult their physicians and discuss
options for screening before following through with any particular screening recommendation.
This form of screening differs from selective screening, in that low-risk women would also have
the option of being screened per their choosing and despite the existence of a recommendation that
excludes them from the risk pool. This form of screening also differs from a universal screening
framework in that it minimizes added costs of overdiagnosis, misdiagnosis, and unnecessary
testing that are a symptom of screening all individuals regardless of risk factors.
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Moreover, healthcare plans face the danger of only covering screening mammograms
based on the USPSTF guidelines. The revised guidelines may limit access to mammography for
22 million women between ages 40 and 49 (“USPSTF Guidelines” 2016). By assigning breast
cancer screening a “C” grade for women under 50, insurance companies will no longer be required
to offer screenings without a copay, which was previously guaranteed by the Affordable Care Act.
Given that coverage of preventive services without copays increases the likelihood that lowincome and minority women receive important health care services, such as mammography, this
recommendation may serve to increase the health disparity in the United States. Therefore, the
future of screening mammography coverage is contentious and potentially life-threatening if not
approached with careful consideration of the pool of women who will be without access to
preventive services if they lose coverage for routine screening mammograms.
Shortcomings and Future Research
The most significant shortcoming is the fact that data were extracted from a national
survey. Therefore, all responses were reported by individuals who completed the survey and
should subsequently not be taken as definitive. Omitted variable bias is another potential
shortcoming given that there were several factors that could not be controlled for such as income
or other potential predictors of health behavior. Such variables that were not included in the
regression were either not asked in the 2015 National Health Interview Survey or they were
excluded due to many missing observations.
Future research should look more closely at the relationship examined in this analysis but
with a dataset that is not based on observations that are self-reported. Moreover, future research
should look at whether or not the USPSTF revised recommendations significantly impacts breast
cancer related outcomes. Future research should also look at understanding the true cost of a false
positive and whether or not a false positive outcome affects health behaviors in the future. Given
that the dataset comes from a national-level survey, although the results can be considered
generalizable to the national population, they should not be interpreted as necessarily causal
considering the source of the data was a self-reported survey and therefore is subject to response
bias.
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9. Appendix

Table 1: Breast Imaging Reporting and Data System, Source:
https://www.cancer.org/cancer/breast-cancer/screening-tests-and-earlydetection/mammograms/understanding-your-mammogram-report.html
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Figure 3: Female Breast Cancer Death Rates in the United States by Race and Ethnicity (19992014). Source: CDC’s National Program of Cancer Registries and National Cancer Institute’s
Surveillance, Epidemiology, and End Results program.

Table 17: Model 1 (Sample 1) Summary statistics. Source: 2015 NHIS
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Table 18: Model 2 (Sample 2) Summary Statistics. Source: 2015 NHIS

Table 19: Model 3 (Sample 3) Summary Statistics. Source: 2015 NHIS

